Priorities for screening and treatment of latent tuberculosis infection in the United States

American Journal of Respiratory and Critical Care Medicine

Volumn 184, Issue 5, 2011, Pages 590-601

  Linas, Benjamin P ^a,b   Wong, Angela Y ^a   Freedberg, Kenneth A ^a,b,c   Horsburgh Jr , C Robert ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD UNIVERSITY   (United States)

Author keywords

Cost effectiveness; Interferon release assay; Latent tuberculosis; Tuberculin skin test

Indexed keywords

ISONIAZID;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS INFECTION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCREENING; TUBERCULIN TEST; TUBERCULOSIS; UNITED STATES; VULNERABLE POPULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CONTACT TRACING; COST SAVINGS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INCIDENCE; INTERFERON-GAMMA; LATENT TUBERCULOSIS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, ECONOMIC; MORBIDITY; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; TUBERCULIN TEST; UNITED STATES; YOUNG ADULT;

EID: 80052501982     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201101-0181OC     Document Type: Article

References (96)

1. Geng E, Kreiswirth B, Driver C, Li J, Burzynski J, DellaLatta P, LaPaz A, Schluger NW. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med 2002;346:1453-1458. (Pubitemid 34755713)
2. Small PM, Hopewell PC, Singh SP, Paz A, Parsonnet J, Ruston DC, Schecter GF, Daley CL, Schoolnik GK. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med 1994;330:1703-1709.
3. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161: S221-S247.
4. Mazurek M, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States. MMWR Recomm Rep 2010;59:1-25.
5. Rose DN. Benefits of screening for latent Mycobacterium tuberculosis infection. Arch Intern Med 2000;160:1513-1521. (Pubitemid 30327457)
6. Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: A risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997; 127:1051-1061. (Pubitemid 28012074)
7. Taylor Z. The cost-effectiveness of screening for latent tuberculosis infection. Int J Tuberc Lung Dis 2000;4:S127-S133. (Pubitemid 32046271)
8. Fitzgerald JM, Gafni A. A cost-effectiveness analysis of the routine use of isoniazid prophylaxis in patients with a positive Mantoux skin test. Am Rev Respir Dis 1990;142:848-853. (Pubitemid 20344656)
9. Comstock GW, Woolpert SF, Livesay VT. Tuberculosis studies in Muscogee County, Georgia. Twenty-year evaluation of a community trial of BCG vaccination. Public Health Rep 1976;91:276-280.
10. Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. BMJ 1977;2: 293-295. (Pubitemid 8153940)
11. Horwitz O, Wilbek E, Erickson PA. Epidemiological basis of tuberculosis eradication. 10. Longitudinal studies on the risk of tuberculosis in the general population of a low-prevalence area. Bull World Health Organ 1969;41:95-113.
12. Marra F, Marra CA, Sadatsafavi M, Moran-Mendoza O, Cook V, Elwood RK, Morshed M, Brunham RC, Fitzgerald JM. Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts. Int J Tuberc Lung Dis 2008;12:1414-1424.
13. de Perio MA, Tsevat J, Roselle GA, Kralovic SM, Eckman MH. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Arch Intern Med 2009;169:179-187.
14. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: A cost-effectiveness analysis. Int J Tuberc Lung Dis 2007;11:16-26. (Pubitemid 46101841)
15. US Census Bureau. United States, regions, States and Puerto Rico population estimates and population change. Washington, D.C.: U.S. Census Bureau; 2004.
16. Oeltmann JE, Kammerer JS, Pevzner ES, Moonan PK. Tuberculosis and substance abuse in the United States, 1997-2006. Arch Intern Med 2009;169:189-197.
17. Bennett DE, Courval JM, Onorato I, Agerton T, Gibson JD, Lambert L, McQuillan GM, Lewis B, Navin TR, Castro KG. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med 2008;177:348-355. (Pubitemid 351198380)
18. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004;350:2060-2067.
19. Horsburgh CR Jr, O'Donnell M, Chamblee S, Moreland JL, Johnson J, Marsh BJ, Narita M, Johnson LS, von Reyn CF. Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med 2010;182:420-425.
20. CDC. Reported tuberculosis in the United States, 2007. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control; 2008.
21. Linas BP, Wong AW, Freedberg KA, Horsburgh CR. The cost effectiveness of tuberculin skin test and interferon gamma release assay screening for latent tuberculosis infection in the US [abstract]. Presented at the ATS 2011 International Conference; May 13-18, 2011, Denver, CO.
22. United States Government. Office of Management and Budget. Historical Tables - Budget of the US Government [accessed 2011 Apr 22] Available from: http://www.gpoaccess.gov/usbudget/fy11/pdf/hist.pdf.
23. Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR. Guidelines for pharmacoeconomic studies. Recommendations from the Panel on Cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997;11:159-168. (Pubitemid 27086806)
24. Dewan PK, Grinsdale J, Liska S, Wong E, Fallstad R, Kawamura LM. Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC Infect Dis 2006;6:47.
25. Harada N, Higuchi K, Yoshiyama T, Kawabe Y, Fujita A, Sasaki Y, Horiba M, Mitarai S, Yonemaru M, Ogata H, et al. Comparison of the sensitivity and specificity of two whole blood interferon-gamma assays for M. tuberculosis infection. J Infect 2008;56:348-353.
26. Detjen AK, Keil T, Roll S, Hauer B, Mauch H, Wahn U, Magdorf K. Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin Infect Dis 2007;45: 322-328. (Pubitemid 47101028)
27. Lee JY, Choi HJ, Park IN, Hong SB, Oh YM, Lim CM, Lee SD, Koh Y, Kim WS, Kim DS, et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006;28:24-30. (Pubitemid 44914256)
28. Palazzo R, Spensieri F, Massari M, Fedele G, Frasca L, Carrara S, Goletti D, Ausiello CM. Use of whole-blood samples in in-house bulk and single-cell antigen-specific gamma interferon assays for surveillance of Mycobacterium tuberculosis infections. Clin Vaccine Immunol 2008;15:327-337. (Pubitemid 352025523)
29. Ruhwald M, Bodmer T, Maier C, Jepsen M, Haaland MB, Eugen-Olsen J, Ravn P. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J 2008;32:1607-1615.
30. Aichelburg MC, Rieger A, Breitenecker F, Pfistershammer K, Tittes J, Eltz S, Aichelburg AC, Stingl G, Makristathis A, Kohrgruber N. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis 2009;48:954-962.
31. Bartu V, Havelkova M, Kopecka E. QuantiFERON-TB Gold in the diagnosis of active tuberculosis. J Int Med Res 2008;36:434-437. (Pubitemid 351833592)
32. Chee CB, Gan SH, Khinmar KW, Barkham TM, Koh CK, Liang S, Wang YT. Comparison of sensitivities of two commercial gamma interferon release assays for pulmonary tuberculosis. J Clin Microbiol 2008;46:1935-1940. (Pubitemid 351831823)
33. Tsiouris SJ, Coetzee D, Toro PL, Austin J, Stein Z, El-Sadr W. Sensitivity analysis and potential uses of a novel gamma interferon release assay for diagnosis of tuberculosis. J Clin Microbiol 2006;44:2844-2850. (Pubitemid 44228579)
34. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-1018. (Pubitemid 29143893)
35. Horsburgh R, Goldberg S, Bethel J, Colson P, Hirsch-Moverman Y, Hughes S, Shrestha-Kuwahara R, Sterling T, Wall K, Weinfurter P. Low latent tuberculosis infection treatment completion with a 9-month INH regimen [abstract]. Am J Respir Crit Care Med 2007;175:A24.
36. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial. Bull World Health Organ 1982;60:555-564.
37. Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med 2000;162:2033-2038. (Pubitemid 32051659)
38. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970;26:28-106.
39. Winston CA, Navin TR. Birth cohort effect on latent tuberculosis infection prevalence, United States. BMC Infect Dis 2010;10:206.
40. Borgdorff MW, Behr MA, Nagelkerke NJ, Hopewell PC, Small PM. Transmission of tuberculosis in San Francisco and its association with immigration and ethnicity. Int J Tuberc Lung Dis 2000;4:287-294. (Pubitemid 30194101)
41. Dion MJ, Tousignant P, Bourbeau J, Menzies D, Schwartzman K. Measurement of health preferences among patients with tuberculous infection and disease. Med Decis Making 2002;22:S102-S114.
42. Dion MJ, Tousignant P, Bourbeau J, Menzies D, Schwartzman K. Feasibility and reliability of health-related quality of life measurements among tuberculosis patients. Qual Life Res 2004;13:653-665. (Pubitemid 38526539)
43. Marra CA, Marra F, Colley L, Moadebi S, Elwood RK, Fitzgerald JM. Health-related quality of life trajectories among adults with tuberculosis: differences between latent and active infection. Chest 2008; 133:396-403. (Pubitemid 351272397)
44. US Department of Labor. Bureau of Labor Statistics. Consumer Price Index All Urban Consumers (CPI-U). US city average 1913-2010 [accessed 2011 Mar 31]. Available from: ftp://ftp.bls.gov/pub/special. requests/cpi/cpiai.txt.
45. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR 3rd, Moore RD, Freedberg KA. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006;44:990-997. (Pubitemid 44674030)
46. Foster TS, Miller JD, Marton JP, Caloyeras JP, Russell MW, Menzin J. Assessment of the economic burden of COPD in the US: a review and synthesis of the literature. COPD 2006;3:211-218. (Pubitemid 44949061)
47. Medical Expenditure Panel Survey (MEPS). Household Component Summary Tables. In: Agency for Healthcare Research and Quality. Washington, D.C.: US Department of Health and Human Services; 2005.
48. American Diabetes Association. Economic costs of diabetes in the US In 2007. Diabetes Care 2008;31:596-615.
49. United States Renal Data System. 2008 Annual Data Report. Volume 2. Atlas of end stage renal disease. Table 11 - Costs of end stage renal disease [accessed 2011 Jan 3]. Available from: http://www.usrds.org/atlas.htm.
50. Indicators of disease burden and the burden of obesity. National Institute of Health [accessed 2011 Jan 3]. Available from: http://dpcpsi. nih.gov/council/pdf/CoC-112008-Shuttinga-Burden.pdf.
51. Silverman S, Dukes EM, Johnston SS, Brandenburg NA, Sadosky A, Huse DM. The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis. Curr Med Res Opin 2009;25: 829-840.
52. Office of National Drug Control Policy. The economic costs of drug abuse in the United States, 1992-1998. Washington, DC: Executive Office of the President (Publication No. NCJ-190636); 2001.
53. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003;163:1637-1641. (Pubitemid 36898950)
54. US Census Bureau. Foreign-born population of the United States current population survey-March 2004 detail tables [accessed 2011 Jan 3]. Available from: http://www.census.gov/population/www/socdemo/ foreign/ppl-176.html.
55. Campsmith ML, Rhodes P, Hall HI, Green T. HIV prevalence estimates-United States, 2006. MMWR Morb Mortal Wkly Rep 2008;57: 1073-1076.
56. United States Department of Homeland Security. Yearbook of immigration statistics: 2007. Washington, DC: Department of Homeland Security; 2008.
57. US Department of Housing and Urban Development. The annual homeless assessment report to Congress [accessed 2009 Mar 22]. Available from: http://www.huduser.org/portal/publications/povsoc/ ahar-5.html.
58. Armstrong GL. Injection drug users in the United States, 1979-2002: An aging population. Arch Intern Med 2007;167:166-173. (Pubitemid 46148064)
59. Mutlu GM, Mutlu EA, Bellmeyer A, Rubinstein I. Pulmonary adverse events of anti-tumor necrosis factor-alpha antibody therapy. Am J Med 2006;119:639-646. (Pubitemid 44128443)
60. Bureau of Justice Statistics. Prison inmates at midyear 2009 - statistical tables. Office of Justice Programs. Washington, DC: U.S. Department of Justice; 2010.
61. National Health and Nutrition Examination Survey (NHANES) [accessed 2011 Mar 22]. Available from: http://www.cdc.gov/nchs/data/hestat/underweight-adult- 07-08/underweight-adult-07-08. htm.
62. Santry HP, Gillen DL, Lauderdale DS. Trends in bariatric surgical procedures. JAMA 2005;294:1909-1917. (Pubitemid 41464692)
63. Kane F. The campaign to end silicosis. Job Safety & Health Quarterly 1997 Winter/Spring. (Accessed August 4, 2011.) Available from: http://www.osha.gov/dsg/topics/silicacrystalline/endsilicosis.html
64. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
65. US Renal Data System. USRDS 2010 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2010.
66. Hunink M, Glasziou P, Siegel J, Weeks J, Pliskin J, Elstein A, Weinstein MC. Decision making in health and medicine: integrating evidence and values. Cambridge: Cambridge University Press; 2001.
67. Cain KP, Haley CA, Armstrong LR, Garman KN, Wells CD, Iademarco MF, Castro KG, Laserson KF. Tuberculosis among foreign-born persons in the United States: achieving tuberculosis elimination. Am J Respir Crit Care Med 2007;175:75-79. (Pubitemid 46105312)
68. Tosteson AN, Stout NK, Fryback DG, Acharyya S, Herman BA, Hannah LG, Pisano ED. Cost-effectiveness of digital mammography breast cancer screening. Ann Intern Med 2008;148:1-10. (Pubitemid 351664941)
69. Sonnenberg A, Delco F, Inadomi JM. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 2000;133:573-584.
70. Nolan CM, Elarth AM. Tuberculosis in a cohort of Southeast Asian refugees. A five-year surveillance study. Am Rev Respir Dis 1988;137:805-809. (Pubitemid 18099289)
71. Blum RN, Polish LB, Tapy JM, Catlin BJ, Cohn DL. Results of screening for tuberculosis in foreign-born persons applying for adjustment of immigration status. Chest 1993;103:1670-1674. (Pubitemid 23174295)
72. Collaboration ATC. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet 2008;372:293-299.
73. Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, Geborek P. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:670-675. (Pubitemid 46707138)
74. Friedman L. Tuberculosis screening in alcoholics and drug addicts. Am Rev Respir Dis 1988;138:239.
75. Hibbs JR, Benner L, Klugman L, Spencer R, Macchia I, Mellinger A, Fife DK. Mortality in a cohort of homeless adults in Philadelphia. N Engl J Med 1994;331:304-309. (Pubitemid 24236019)
76. Bock NN, Metzger BS, Tapia JR, Blumberg HM. A tuberculin screening and isoniazid preventive therapy program in an inner-city population. Am J Respir Crit Care Med 1999;159:295-300. (Pubitemid 29036538)
77. Zolopa AR, Hahn JA, Gorter R, Miranda J, Wlodarczyk D, Peterson J, Pilote L, Moss AR. HIV and tuberculosis infection in San Francisco's homeless adults. Prevalence and risk factors in a representative sample. JAMA 1994;272:455-461. (Pubitemid 24235695)
78. Reichman LB, Felton CP, Edsall JR. Drug dependence, a possible new risk factor for tuberculosis disease. Arch Intern Med 1979;139:337-339. (Pubitemid 10128425)
79. Shah NG, Galai N, Celentano DD, Vlahov D, Strathdee SA. Longitudinal predictors of injection cessation and subsequent relapse among a cohort of injection drug users in Baltimore, MD, 1988-2000. Drug Alcohol Depend 2006;83:147-156. (Pubitemid 44208952)
80. Friedman LN, Sullivan GM, Bevilaqua RP, Loscos R. Tuberculosis screening in alcoholics and drug addicts. Am Rev Respir Dis 1987;136: 1188-1192. (Pubitemid 17151085)
81. Sabol WJ, Couture H. Prison inmates at midyear 2007. US Department of Justice, Bureau of Justice Statistics. Washington, DC; 2008 [accessed 2011 Jan 3]. Available from: http://bjs.ojp.usdoj.gov/content/pub/pdf/pim07.pdf.
82. Lobato MN, Leary LS, Simone PM. Treatment for latent TB in correctional facilities: a challenge for TB elimination. Am J Prev Med 2003;24:249-253. (Pubitemid 36349132)
83. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, Lamonte MJ, Stroup AM, Hunt SC. Long-term mortality after gastric bypass surgery. N Engl J Med 2007;357:753-761. (Pubitemid 47295642)
84. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005;293: 1861-1867. (Pubitemid 40548182)
85. Centers for Disease Control and Prevention. Silicosis-related years of potential life lost before age 65 years-United States, 1968-2005. MMWR Morb Mortal Wkly Rep 2008;57:771-775.
86. Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med 2007; 147:149-155. (Pubitemid 351664594)
87. Holland DP, Sanders GD, Hamilton CD, Stout JE. Costs and costeffectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 2009;179:1055-1060.
88. Mofenson LM, Brady MT, Danner SP, Dominguez KL, Hazra R, Handelsman E, Havens P, Nesheim S, Read JS, Serchuck L, et al. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009;58:1-166.
89. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, Gordin F, Horsburgh CR, Horton J, Khan A, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002;360:528-534.
90. Salpeter EE, Salpeter SR. Mathematical model for the epidemiology of tuberculosis, with estimates of the reproductive number and infection-delay function. Am J Epidemiol 1998;147:398-406. (Pubitemid 28106895)
91. Drug Topics Red Book, 112th ed. New York: Thomson Healthcare; 2008.
92. Center for Medicare Services. US Department of Health and Human Services. 2008 National fee schedule relative value file [accessed 2010 May 25]. Available from: http://www.cms.hhs.gov/PhysicianFeeSched/PFSRVF/itemdetail.asp? filterType=none&filterByDID=-99&sortByDID=1&sortOrder= ascending&itemID=CMS1205008&intNumPerPage=10.
93. Center for Medicare Services. US Department of Health and Human Services. 2008 Clinical diagnostic laboratory fee schedule [accessed 2010 May 25]. Available from: http://www.cms.hhs.gov/ClinicalLabFeeSched/02-clinlab. asp#TopOfPage.
94. Medicare RBRVS. The physician's guide. Chicago: American Medical Association; 2008.
95. Holmquist L, Russo CA, Elizhauser A. Tuberculosis stays in US hospitals, 2006. HCUP Statistical Brief #60. October 2008. Agency for Healthcare Research and Quality, Rockville, MD [accessed 2011 Jan 3]. Available from: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb60.pdf.
96. Taylor Z, Marks SM, Rios Burrows NM, Weis SE, Stricof RL, Miller B. Causes and costs of hospitalization of tuberculosis patients in the United States. Int J Tuberc Lung Dis 2000;4:931-939.